LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the release of abstracts on alisertib to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting will be held at McCormick Place in Chicago and online from May 31-June 4..

洛杉矶--（商业新闻短讯）--生物制药公司Puma Biotechnology，Inc.（纳斯达克：PBYI）宣布发布alisertib摘要，将在2024年美国临床肿瘤学会（ASCO）年会上发表。ASCO年会将于5月31日至6月4日在芝加哥的McCormick Place和在线举行。。

Full abstracts of the following posters are available online at https://conferences.asco.org/am/abstracts.

以下海报的完整摘要可在网上查阅https://conferences.asco.org/am/abstracts.

Abstract 1037: Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC 041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC)

摘要1037:TBCRC 041中利用无细胞DNA（cfDNA）和循环肿瘤细胞（CTC）对连续液体活检标本进行分子分析：alisertib在内分泌抵抗性转移性乳腺癌（MBC）中的II期研究

Presenter: Karthik Giridhar, MD., Mayo Clinic

主持人：梅奥诊所医学博士Karthik Giridhar

Abstract 8572: Phase I/Ib study of the aurora kinase A Inhibitor alisertib in combination with osimertinib in advanced osimertinib-resistant EGFR-mutated lung cancer

摘要8572:aurora激酶A抑制剂alisertib联合osimertinib治疗晚期osimertinib耐药EGFR突变肺癌的I/Ib期研究

Presenter: Turja Chakrabarti, MD., University of California, San Francisco

主持人：加利福尼亚大学旧金山分校医学博士Turja Chakrabarti

About Puma Biotechnology:

关于Puma Biotechnology：

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S.

Puma Biotechnology，Inc.是一家生物制药公司，专注于创新产品的开发和商业化，以增强癌症护理。Puma in于2011年将全球开发和商业化权利授予PB272（neratinib，oral）。口服奈拉替尼已获得美国批准。

Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti- HER2-based regimens in the metastatic setting.

美国食品和药物管理局于2017年7月对早期HER2过表达/扩增乳腺癌的成年患者进行了延长辅助治疗，随后进行了基于曲妥珠单抗的辅助治疗，并在美国以NERLYNX®（neratinib）片剂的形式销售。2020年2月，NERLYNX还被FDA批准与卡培他滨联合用于治疗晚期或转移性HER2阳性乳腺癌的成年患者，这些患者在转移性环境中接受了两种或更多种先前基于抗HER2的方案。

NERLYNX was granted marketing authorization by the European Commission in September 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy.

NERLYNX于2018年9月获得欧盟委员会的上市授权，用于延长早期激素受体阳性HER2过表达/扩增乳腺癌的成年患者的辅助治疗，这些患者在完成之前的曲妥珠单抗辅助治疗后不到一年。

NERLYNX® is a registered trademark of Puma Biotechnology, Inc..

NERLYNX®是Puma Biotechnology，Inc.的注册商标。。

In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.

2022年9月，Puma就抗癌药物alisertib（一种选择性小分子口服极光激酶a抑制剂）的开发和商业化签订了独家许可协议。最初，Puma打算将alisertib的开发重点放在治疗小细胞肺癌和乳腺癌上。

In February 2024, Puma initiated ALISCA-Lung 1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer..

2024年2月，Puma启动了ALISCA Lung 1，这是alisertib单药治疗广泛期小细胞肺癌患者的II期临床试验。。

Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

有关Puma生物技术的更多信息，请访问https://www.pumabiotechnology.com.